--- a
+++ b/clusters/9knumclustersv2/clust_101.txt
@@ -0,0 +1,52 @@
+Metastatic breast cancer that is measurable (Stage ) or early breast cancer with a primary tumor size greater than (>)  centimeter (cm) (Stage )
+Clinical stage I or II breast cancer for which there will be at least a  week period of time between diagnosis and definitive surgery
+Early stage (curable) breast cancer
+Patients must have a histologically confirmed HER positive breast cancer (by immunohistochemistry [IHC] + or fluorescence in situ hybridization [FISH] ratio >= .)\r\n* Phase I: unresectable locally advanced or metastatic breast cancer\r\n* Phase II: clinical stage - early stage breast cancer
+Clinical evidence for a stage T or T breast cancer
+Pathologic or clinical evidence for a stage T breast cancer
+The patient must have clinical node negative, stage I breast cancer
+COHORT II: The patient must have clinical node negative, stage I breast cancer
+Subjects must be females with a histological diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer clinical stage T-, N and be candidates for primary resection of this cancer; NOTE: subjects with bilateral cancer are eligible\r\n* Primary tumor stage T- at the time of initial diagnosis and ipsilateral nodes must be N- by clinical evaluation; staging is routinely based on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines and TNM Nomenclature for Breast Cancer from American Joint Committee on Cancer (AJCC) Cancer Staging Manual; all breast cancer patients routinely undergo axillary ultrasound to evaluate nodal involvement
+The patient must have stage , I, or II breast cancer; if stage II, the tumor size must be  cm or less
+New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.
+New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.
+Subjects with advanced stage breast cancer
+Stage II through IIIC HER-/erbB- positive breast cancer with node positive disease.
+Locally advanced or inflammatory breast cancer (stage IIIA to IIIC)
+Early stage breast cancer (stage I [tumor size >=  cm], II and IIIA)
+Early stage breast cancer (Tc-, cN-, cM)
+Histologically confirmed stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)
+Experiencing their first, stage   IIIA breast cancer diagnosis (either clinical or definitive early stage at enrollment)
+Histologically confirmed diagnosis of early stage breast cancer (stage I-III)
+PATIENT: Confirmed medical diagnosis of breast or thoracic cancer regardless of stage and followed at DCC for management
+Diagnosed with any stage breast, GI, or lung cancer
+Diagnosed with stage , I, II, or IIIa breast cancer, confirmed by medical record
+Women who have been diagnosed with stage I-IIIA breast cancer will be recruited - years after the completion of all primary cancer treatment except for longer-term hormonal therapies (tamoxifen, aromatase inhibitors); recruit women who have received one of the two most common stage I-IIIA chemotherapy regimens, either docetaxel/cyclophosphamide or doxorubicin/cyclophosphamide followed by paclitaxel to provide uniformity of prior treatment
+Have breast cancer stage -IIIA
+A diagnosis of local regional breast cancer (stage -IIIa)
+Had a previous diagnosis of breast cancer (any type or stage) as confirmed by official medical records
+Has been diagnosed with early-stage breast cancer
+Women previously diagnosed with stage -IIIA breast cancer
+Histologically confirmed stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)
+New diagnosis of breast cancer stage -
+Stage  or  breast cancer or any other concurrent malignancy including hematological malignancies (i.e. leukemia or lymphoma)
+In early survivorship phase, defined as being - months post completion of treatment for stage - breast cancer
+PHASE I: Has a first, primary diagnosis of unilateral stage , , , or a breast cancer (patients with bilateral breast cancer will be excluded from participation)
+PHASE II: Has a first, primary diagnosis of unilateral stage , , , or a breast cancer
+Completed treatment for stage - breast cancer at least two months but not more than  months prior to enrollment.
+Women with stage - breast cancer who are within first two rounds of chemotherapy OR women who have stage  breast cancer at initial diagnosis and are initiating first line chemotherapy; note: women with stage  breast cancer must have an Eastern Cooperative Oncology Group (ECOG) performance status of  or 
+Women with a history of cancer, any stage, with breast or gynecologic cancer
+Stage -IIIA breast cancer survivors and their partner
+Stage A  B breast cancer diagnosis
+Stage I and II breast cancer patients undergoing active radiation therapy
+Have a diagnosis of breast cancer, any stage.
+Previous diagnosis of stage  cancer
+BREAST CANCER SURVIVORS: Has histologically-confirmed, first-time breast cancer (stage I-IIIB);
+Diagnosis of stage I-IIIA breast cancer within past  years (confirmed by medical record review)
+Pathologically confirmed diagnosis of breast cancer, clinical stage I-II (T- N M, T- N M); diagnosis must be by needle biopsy; patients diagnosed by surgical excision are excluded; for patients enrolled after receipt and completion of neoadjuvant chemotherapy, the clinical stage must be determined based on pre-chemotherapy assessment
+Breast cancer (any stage)
+The patient must have a histologically proven diagnosis of stage I through IIIC breast cancer
+Participants who are breast cancer free (mammogram negative within  month of testing) with the absence of clinical suspicion of breast cancer on physical exam or with stage II or stage III breast cancer will be invited to participate in the study
+Patients without known bone metastases who are newly diagnosed with ? stage  breast cancer, ? stage  lung cancer, or ? stage  prostate cancer (and/or PSA > micrograms/L), including patient with recurrent breast, lung or prostate cancer
+Stage  breast cancer
+First diagnosis with stage - breast or stage - lung cancer; and voluntary participation